My name is Maroeska te Loo, medical staff member of Pediatric Hematology at the department of Pediatrics of the Amalia Childrens Hospital. I am currently working in the theme Rare cancers.
When you were a kid, what did you want to be when you grew up? Can you tell us something about your child years?"As a child I wanted to become an archaeologist. I thought it was wonderful to go outside and look for shards, old things and then make a whole of it. When I was 10, however, my mother developed cancer and became very ill. At some point in time, the doctors thought she would die and I had to say goodbye as a 10-year-old. I did not understand the impact and asked what I could do to help. The intensivist indicated that I was still too small to help large people and to understand the problems there where. From that moment on, I only wanted one thing: to become a doctor to help small people. I never let go of that thought again and through high school, medical school etc. I only wanted to become a pediatrician that would make the difference. I still look for pieces, however, the pieces that I am looking for are: learning more about the pathogenesis of diseases and finding new solutions for treatment or improve current treatment."
What was your previous academic training, where did you study and why that study?"As mentioned above I already knew as a child that I wanted to become a pediatrician. For this, I studied medicine in Nijmegen, followed by my PhD thesis on Hemolytic uremic syndrome in pediatrics. Subsequently, I started my training to become a pediatrician first and later a pediatric hematologist and oncologist. During my fellow period as pediatric hematologist I received my first personal grant to study pharmacogenetics of osteosarcoma. Knowledge regarding pharmacological aspects forms the corner stone of my research. For this reason I started my training as clinical pharmacologist in 2009."
The RIMLS motto is: ‘Today’s molecules for tomorrow’s medicine’. What does this mean for you?"Based on the genetic profiles of the diseases of the patients I hope to find new druggable targets. And by using pharmacogenomics I hope to improve current treatment strategies to enhance efficacy and reduce adverse events seen in patients."
Who is your great example as scientists? And why?"In fact my greatest example was my promotor prof. Leo Monnens PhD. He was always working to improve medical care of children and always linked the clinic with scientific research and vice versa. His integrity, his enthusiasm and his personal care have always been a great example for me."
Which research discovery that you have made has made you most proud?"At this moment we are performing a clinical trial with the drug Sirolimus in patients with a congenital vascular malformation that had no other treatment options anymore. Patients with these vascular malformation suffer of severe pain due local increased coagulation and infections. Sirolimus is a drug that inhibits the mTOR pathway, which is upregulated in these patients due mutations in the PIK3CA pathway. By inhibiting the mTOR pathway we hoped to make a difference for this patients. The trial with Sirolimus runs now for several years: for me, it is still a wonder to see how life of about 70% of the patients have changed by introducing Sirolimus. 70% of the patients has less or even no pain anymore, quality of life improved significantly and patients can participate in normal daily activities. Interestingly, in 30% of the patients we observed a reduction in the size of the vascular malformation."
Given unlimited finance what experiment would you perform?"That is a difficult question as I would not perform only one experiment. I have a lot of ideas how to improve current medical treatment in pediatrics for example by introducing an nationwide pharmacovigilance system and pharmacogenetic testing. On the other hand I would like to unravel more about the pathogenesis of the vascular malformations, gain insight why there is local intravascular coagulation and which factors contribute. Furthermore, I would like to gain insight in the genetic signature of these vascular malformations to find new druggable targets."
What does your working area look like and what does it say about you or your research?"My work area is very clean and organized. I like to be organized in both my medical tasks and my research."
Nominate a colleague to be in the spotlight:"Marieke Coenen, department of Genetics."
What type of person are you? Quick insights:a) Mac or PC? : Mac
b) Theater or cinema? : Theater
c) Dine out or dine in? : Dine out
d) Ferrari or Fiat? : Ferrari
e) Shopaholic or chocoholic? : Chocoholic
f) Culture or Nature : Nature
Related news items
RIMLS award ceremony proudly presenting the winners16 January 2020
Several RIMLS researchers received an award and bonus during the New Year's drinks. See all photo's and the ENABLE aftermovie.read more
Stofwisselkracht grant for Daan Panneman and Richard Rodenburg16 January 2020
Daan Panneman & Richard Rodenburg have been awarded a Stofwisselkracht grant for their proposal “CRISPR/Cas9 knock-in complementation in fibroblasts of mitochondrial disease patients”. Together with Omar Tutakhel & Jan Smeitink they will investigate the possibility of using CRISPR/Cas9 knock-in.read more
Radboud Talks 2020 scientific pitch competition14 January 2020
The next edition of Radboud Talks will take place in the spring. During this academic pitch competition, young researchers will be given the opportunity to share their stories with a large audience. In a three-minute presentation, you will talk about your research in a fun and accessible manner.read more
Rubicon Grant for Sami Mohammed14 January 2020
Former RIMLS researcher Sami Mohammed, theme Renal disorders, received a Rubicon Grant from the Dutch Organisation for Scientific Research (NWO). The Rubicon program gives young, highly promising researchers the opportunity to gain international research experience.read more
Review Sanne Frambach accepted by Pharmacological Reviews13 January 2020
In this review entitled 'Brothers in arms: ABCA1 and ABCG1-mediated cholesterol efflux as promising targets in cardiovascular disease treatment', RIMLS researcher Sanne Frambach, describe the possibilities for stimulating cellular efflux.read more
p120-catenin-dependent collective brain infiltration by glioma cell networks7 January 2020
Pavlo Gritsenko and Peter Friedl, theme Cancer development and immune defense, report in Nature Cell Biology, that glioma cells infiltrate the brain by a collective network mechanism, which critically depends on p120 catenin. p120 thus represents a potential target to combat glioma.read more